Medicine put to the test

The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Advanced heart failure: telemonitoring reduces cardiovascular mortality

2019-10-28 If patients are actively involved in telemonitoring, all-cause mortality is also lower – as long as they do not show depressive symptoms.

read more Link to \Advanced heart failure: telemonitoring reduces cardiovascular mortality\""

Liver transplantations: Better results with larger case numbers

2019-10-02 In hospitals with many liver transplantations, the chances of survival are higher. However, there are no studies on the effects of specific minimum case numbers introduced into health care.

read more Link to \Liver transplantations: Better results with larger case numbers\""

Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations

2019-09-19 After a methodological uncertainty has been resolved, the analyses on overall survival are now usable. Two addenda now show an added benefit for specific patients.

read more Link to \Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations\""

Newborn screening for sickle cell disease can prevent deaths

2019-09-19 Earlier diagnosis of sickle cell disease combined with prevention of infections and education of relatives increases the life expectancy of affected children.

read more Link to \Newborn screening for sickle cell disease can prevent deaths\""

Biologics in rheumatoid arthritis: better evidence, but direct comparisons still lacking

2019-09-17 Studies on biologics are too short and too often include placebo controls – this hampers comparisons of biologics; however, due to new data provided by companies, new findings are available

read more Link to \Biologics in rheumatoid arthritis: better evidence, but direct comparisons still lacking\""

HTA in the European network: osteoporosis screening without proof of benefit

2019-09-16 For the first time, IQWiG was in charge of a health technology assessment for the European network EUnetHTA. According to the conclusion, the benefit of osteoporosis screening is not proven.

read more Link to \HTA in the European network: osteoporosis screening without proof of benefit\""

Between scalpel and algorithm - evidence-based surgery: the IQWiG Autumn Symposium

2019-09-11 Surgery also needs good evidence: How can the surgically relevant research questions best be tackled? We will discuss this on 29 and 30 November.

read more Link to \Between scalpel and algorithm - evidence-based surgery: the IQWiG Autumn Symposium\""

Dacomitinib in advanced lung cancer: large number of disadvantages outweighs survival advantage

2019-08-01 Longer survival is offset by more frequent – and partly severe – side effects and deterioration in symptoms and quality of life. Overall, an added benefit is not proven.

read more Link to \Dacomitinib in advanced lung cancer: large number of disadvantages outweighs survival advantage\""

Ezetimibe reduces the risk of heart attacks and strokes

2019-07-26 Given in addition to statin therapy, ezetimibe has a preventive effect in patients with CHD and acute coronary syndrome.

read more Link to \Ezetimibe reduces the risk of heart attacks and strokes\""

Early benefit assessment reveals weaknesses in the development of new drugs

2019-07-11 In the British Medical Journal, IQWiG researchers analyse the first 216 AMNOG assessments of new drugs and derive proposals for more targeted drug development.

read more Link to \Early benefit assessment reveals weaknesses in the development of new drugs\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No Title Type Deadline
N18-03Mandibular advancement devices in mild to moderate obstructive sleep apnoea in adults zum Vorbericht 20.11.2019
S18-02Newborn screening for spinal muscular atrophy (SMA) zum Vorbericht 28.11.2019
V19-01Guideline synopsis for the DMP "COPD" zum Vorbericht 10.12.2019

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Olaparib (Lynparza) for the treatment of advanced breast cancer

Olaparib (trade name: Lynparza) has been approved in Germany since April 2019 for the treatment of hormone-receptor-negative breast cancer in adults, if the cancer has already spread to other parts of the body or is locally advanced. This drug is a treatment option for people who have a mutated BRCA gene.   read more (Link to \Olaparib (Lynparza) for the treatment of advanced breast cancer\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close